Chinese Society of Allergy and Chinese Society of Otorhinolaryngology-Head and Neck Surgery Guideline for Chronic Rhinosinusitis
- Author:
Zheng LIU
1
;
Jianjun CHEN
;
Lei CHENG
;
Huabin LI
;
Shixi LIU
;
Hongfei LOU
;
Jianbo SHI
;
Ying SUN
;
Dehui WANG
;
Chengshuo WANG
;
Xiangdong WANG
;
Yongxiang WEI
;
Weiping WEN
;
Pingchang YANG
;
Qintai YANG
;
Gehua ZHANG
;
Yuan ZHANG
;
Changqing ZHAO
;
Dongdong ZHU
;
Li ZHU
;
Fenghong CHEN
;
Yi DONG
;
Qingling FU
;
Jingyun LI
;
Yanqing LI
;
Chengyao LIU
;
Feng LIU
;
Meiping LU
;
Yifan MENG
;
Jichao SHA
;
Wenyu SHE
;
Lili SHI
;
Kuiji WANG
;
Jinmei XUE
;
Luoying YANG
;
Min YIN
;
Lichuan ZHANG
;
Ming ZHENG
;
Bing ZHOU
;
Luo ZHANG
Author Information
- Publication Type:Review
- Keywords: Chronic, sinusitis; China; guideline; inflammation; biomarkers; epigenesis; phenotype; endotypes; diagnosis; management
- MeSH: Adult; Asian Continental Ancestry Group; Biomarkers; China; Consensus; Diagnosis; Diagnosis, Differential; Drug Therapy; Eosinophils; Epidemiology; Epigenomics; Genetics; Humans; Hypersensitivity; Inflammation; International Agencies; Medical Staff; Neck; Phenotype; Precision Medicine
- From:Allergy, Asthma & Immunology Research 2020;12(2):176-237
- CountryRepublic of Korea
- Language:English
- Abstract: The current document is based on a consensus reached by a panel of experts from the Chinese Society of Allergy and the Chinese Society of Otorhinolaryngology-Head and Neck Surgery, Rhinology Group. Chronic rhinosinusitis (CRS) affects approximately 8% of Chinese adults. The inflammatory and remodeling mechanisms of CRS in the Chinese population differ from those observed in the populations of European descent. Recently, precision medicine has been used to treat inflammation by targeting key biomarkers that are involved in the process. However, there are no CRS guidelines or a consensus available from China that can be shared with the international academia. The guidelines presented in this paper cover the epidemiology, economic burden, genetics and epigenetics, mechanisms, phenotypes and endotypes, diagnosis and differential diagnosis, management, and the current status of CRS in China. These guidelines—with a focus on China—will improve the abilities of clinical and medical staff during the treatment of CRS. Additionally, they will help international agencies in improving the verification of CRS endotypes, mapping of eosinophilic shifts, the identification of suitable biomarkers for endotyping, and predicting responses to therapies. In conclusion, these guidelines will help select therapies, such as pharmacotherapy, surgical approaches and innovative biotherapeutics, which are tailored to each of the individual CRS endotypes.
